{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,2]],"date-time":"2026-11-02T07:03:33Z","timestamp":1793603013207,"version":"4.5.0"},"reference-count":28,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,3,4]],"date-time":"2026-03-04T00:00:00Z","timestamp":1772582400000},"content-version":"vor","delay-in-days":62,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Cancer Treatment and Research Communications"],"published-print":{"date-parts":[[2026]]},"DOI":"10.1016\/j.ctarc.2026.101169","type":"journal-article","created":{"date-parts":[[2026,3,5]],"date-time":"2026-03-05T09:14:21Z","timestamp":1772702061000},"page":"101169","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"special_numbering":"C","title":["PSMA for HCC: a new frontier in precision medicine for liver cancer?"],"prefix":"10.1016","volume":"47","author":[{"given":"Paola","family":"Caroli","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Virginia","family":"Rossetti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maddalena","family":"Sansovini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lorenzo","family":"Fantini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Irene","family":"Marini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Silvia","family":"Nicolini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ilaria","family":"Grassi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7455-6253","authenticated-orcid":false,"given":"Federica","family":"Matteucci","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Valentina","family":"Di Iorio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Monica","family":"Celli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"3","key":"10.1016\/j.ctarc.2026.101169_bib0001","first-page":"209","article-title":"Global Cancer Statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"71","author":"Sung","year":"2021","journal-title":"CA Cancer J. Clin."},{"issue":"2","key":"10.1016\/j.ctarc.2026.101169_bib0002","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1016\/j.jhep.2024.08.028","article-title":"EASL Clinical Practice Guidelines on the management of hepatocellular carcinoma","volume":"82","year":"2025","journal-title":"J. Hepatol."},{"issue":"2","key":"10.1016\/j.ctarc.2026.101169_bib0003","doi-asserted-by":"crossref","first-page":"723","DOI":"10.1002\/hep.29913","article-title":"Diagnosis, staging, and management of hepatocellular carcinoma: 2018 practice guidance by the American Association for the Study of Liver Diseases","volume":"68","author":"Marrero","year":"2018","journal-title":"Hepatology"},{"issue":"3","key":"10.1016\/j.ctarc.2026.101169_bib0004","doi-asserted-by":"crossref","first-page":"1020","DOI":"10.1002\/hep.24199","article-title":"Management of hepatocellular carcinoma: an update","volume":"53","author":"Bruix","year":"2011","journal-title":"Hepatology"},{"issue":"1","key":"10.1016\/j.ctarc.2026.101169_bib0005","doi-asserted-by":"crossref","first-page":"7","DOI":"10.3350\/cmh.2016.22.1.7","article-title":"A concise review of updated guidelines regarding the management of hepatocellular carcinoma around the world: 2010-2016","volume":"22","author":"Yu","year":"2016","journal-title":"Clin. Mol. Hepatol."},{"issue":"5","key":"10.1016\/j.ctarc.2026.101169_bib0006","doi-asserted-by":"crossref","first-page":"2871","DOI":"10.1007\/s00330-019-06649-z","article-title":"Contrast-enhanced ultrasound for the characterization of portal vein thrombosis vs tumor-in-vein in HCC patients: a systematic review and meta-analysis","volume":"30","author":"Chen","year":"2020","journal-title":"Eur. Radiol."},{"issue":"16","key":"10.1016\/j.ctarc.2026.101169_bib0007","doi-asserted-by":"crossref","DOI":"10.3390\/cancers14163997","article-title":"Current imaging diagnosis of hepatocellular carcinoma","volume":"14","author":"Chartampilas","year":"2022","journal-title":"Cancer. (Basel)"},{"issue":"1","key":"10.1016\/j.ctarc.2026.101169_bib0008","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1148\/radiol.14140690","article-title":"Hepatocellular carcinoma: diagnostic performance of multidetector CT and MR imaging-a systematic review and meta-analysis","volume":"275","author":"Lee","year":"2015","journal-title":"Radiology"},{"issue":"6","key":"10.1016\/j.ctarc.2026.101169_bib0009","doi-asserted-by":"crossref","first-page":"1009","DOI":"10.1007\/s12072-020-10100-7","article-title":"Diagnostic performance of MRI for HCC according to contrast agent type: a systematic review and meta-analysis","volume":"14","author":"Kim","year":"2020","journal-title":"Hepatol. Int."},{"issue":"9","key":"10.1016\/j.ctarc.2026.101169_bib0010","doi-asserted-by":"crossref","first-page":"2417","DOI":"10.1016\/j.ejrad.2011.08.004","article-title":"18F-FDG PET or PET\/CT for detecting extrahepatic metastases or recurrent hepatocellular carcinoma: a systematic review and meta-analysis","volume":"81","author":"Lin","year":"2012","journal-title":"Eur. J. Radiol."},{"issue":"5","key":"10.1016\/j.ctarc.2026.101169_bib0011","doi-asserted-by":"crossref","first-page":"792","DOI":"10.1016\/S0168-8278(00)80248-2","article-title":"Positron emission tomography scanning in the evaluation of hepatocellular carcinoma","volume":"32","author":"Khan","year":"2000","journal-title":"J. Hepatol."},{"issue":"2","key":"10.1016\/j.ctarc.2026.101169_bib0012","first-page":"213","article-title":"11C-acetate PET imaging in hepatocellular carcinoma and other liver masses","volume":"44","author":"Ho","year":"2003","journal-title":"J. Nucl. Med."},{"issue":"2","key":"10.1016\/j.ctarc.2026.101169_bib0013","doi-asserted-by":"crossref","first-page":"336","DOI":"10.1016\/j.jhep.2018.02.018","article-title":"Positron emission tomography\/computed tomography with 18F-fluorocholine improve tumor staging and treatment allocation in patients with hepatocellular carcinoma","volume":"69","author":"Chalaye","year":"2018","journal-title":"J. Hepatol."},{"issue":"5","key":"10.1016\/j.ctarc.2026.101169_bib0014","doi-asserted-by":"crossref","first-page":"852","DOI":"10.1007\/s00259-015-3241-0","article-title":"Diagnostic value of combining \u00b9\u00b9C-choline and \u00b9\u2078F-FDG PET\/CT in hepatocellular carcinoma","volume":"43","author":"Castilla-Li\u00e8vre","year":"2016","journal-title":"Eur. J. Nucl. Med. Mol. ImAging"},{"key":"10.1016\/j.ctarc.2026.101169_bib0015","article-title":"18F-FDG \/18F-choline dual-tracer PET behavior and tumor differentiation in hepatocellular carcinoma. A systematic review","volume":"9","author":"Ghidaglia","year":"2022","journal-title":"Front. Med. (Lausanne)"},{"issue":"4","key":"10.1016\/j.ctarc.2026.101169_bib0016","doi-asserted-by":"crossref","first-page":"302","DOI":"10.1053\/j.semnuclmed.2019.02.008","article-title":"PSMA-targeted radiopharmaceuticals for imaging and therapy","volume":"49","author":"Wester","year":"2019","journal-title":"Semin. Nucl. Med."},{"issue":"12","key":"10.1016\/j.ctarc.2026.101169_bib0017","doi-asserted-by":"crossref","first-page":"4000","DOI":"10.1007\/s00259-022-05884-9","article-title":"PET imaging of hepatocellular carcinoma by targeting tumor-associated endothelium using","volume":"49","author":"Lu","year":"2022","journal-title":"Eur. J. Nucl. Med. Mol. Imaging"},{"issue":"5","key":"10.1016\/j.ctarc.2026.101169_bib0018","doi-asserted-by":"crossref","first-page":"1","DOI":"10.14309\/ctg.0000000000000041","article-title":"Expression of prostate-specific membrane antigen in tumor-associated vasculature predicts poor prognosis in hepatocellular carcinoma","volume":"10","author":"Jiao","year":"2019","journal-title":"Clin. Transl. Gastroenterol."},{"issue":"5","key":"10.1016\/j.ctarc.2026.101169_bib0019","doi-asserted-by":"crossref","first-page":"1172","DOI":"10.1002\/hep4.1861","article-title":"PSMA as a theranostic target in hepatocellular carcinoma: immunohistochemistry and 68Ga\u2010PSMA\u201011 PET using cyclotron\u2010produced 68Ga","volume":"6","author":"Thompson","year":"2022","journal-title":"Hepatol. Commun."},{"issue":"41","key":"10.1016\/j.ctarc.2026.101169_bib0020","doi-asserted-by":"crossref","first-page":"4149","DOI":"10.18632\/oncotarget.27024","article-title":"Prostate-specific membrane antigen expression in hepatocellular carcinoma: potential use for prognosis and diagnostic imaging","volume":"10","author":"Tolkach","year":"2019","journal-title":"Oncotarget"},{"issue":"7","key":"10.1016\/j.ctarc.2026.101169_bib0021","doi-asserted-by":"crossref","first-page":"1248","DOI":"10.1177\/10668969241226705","article-title":"Expression of PSMA in tumor-associated vasculature predicts poorer survival in patients with hepatocellular carcinoma and is likely associated with PD-L1","volume":"32","author":"Li","year":"2024","journal-title":"Int. J. Surg. Pathol."},{"issue":"1","key":"10.1016\/j.ctarc.2026.101169_bib0022","doi-asserted-by":"crossref","first-page":"316","DOI":"10.1007\/s00259-023-06413-y","article-title":"Demonstration of therapy response to radioembolization with","volume":"51","author":"Ozkan","year":"2023","journal-title":"Eur. J. Nucl. Med. Mol. Imaging"},{"issue":"11","key":"10.1016\/j.ctarc.2026.101169_bib0023","doi-asserted-by":"crossref","DOI":"10.3390\/ph15111368","article-title":"Can PSMA-targeting radiopharmaceuticals be useful for detecting hepatocellular carcinoma using positron emission tomography? An updated systematic review and meta-analysis","volume":"15","author":"Rizzo","year":"2022","journal-title":"Pharmaceut. (Basel)"},{"issue":"22","key":"10.1016\/j.ctarc.2026.101169_bib0024","doi-asserted-by":"crossref","DOI":"10.3390\/cancers16223865","article-title":"Prostate-Specific Membrane Antigen (PSMA) PET\/CT in the detection and diagnosis of Hepatocellular Carcinoma (HCC): A systematic review and meta-analysis","volume":"16","author":"Hannah","year":"2024","journal-title":"Cancer. (Basel)"},{"issue":"3","key":"10.1016\/j.ctarc.2026.101169_bib0025","doi-asserted-by":"crossref","first-page":"883","DOI":"10.1007\/s00259-020-05017-0","volume":"48","author":"Kunikowska","year":"2021","journal-title":"Eur. J. Nucl. Med. Mol. Imaging"},{"issue":"2","key":"10.1016\/j.ctarc.2026.101169_bib0026","doi-asserted-by":"crossref","first-page":"185","DOI":"10.2967\/jnumed.118.214833","article-title":"Ga-PSMA is a novel PET-CT tracer for imaging of hepatocellular carcinoma: A prospective pilot study","volume":"60","author":"Kesler","year":"2019","journal-title":"J. Nucl. Med."},{"issue":"9","key":"10.1016\/j.ctarc.2026.101169_bib0027","doi-asserted-by":"crossref","first-page":"1235","DOI":"10.2967\/jnumed.120.257915","article-title":"Ga-PSMA-11 PET\/CT improves tumor detection and impacts management in patients with hepatocellular carcinoma","volume":"62","author":"Hirmas","year":"2021","journal-title":"J. Nucl. Med."},{"issue":"6","key":"10.1016\/j.ctarc.2026.101169_bib0028","doi-asserted-by":"crossref","first-page":"584","DOI":"10.1097\/RLU.0000000000005212","article-title":"Radionuclide therapy with 177 Lu-PSMA in a patient with hepatocellular carcinoma","volume":"49","author":"Pretet","year":"2024","journal-title":"Clin. Nucl. Med."}],"container-title":["Cancer Treatment and Research Communications"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2468294226000808?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2468294226000808?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,6,8]],"date-time":"2026-06-08T11:54:03Z","timestamp":1780919643000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2468294226000808"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026]]},"references-count":28,"alternative-id":["S2468294226000808"],"URL":"https:\/\/doi.org\/10.1016\/j.ctarc.2026.101169","relation":{},"ISSN":["2468-2942"],"issn-type":[{"value":"2468-2942","type":"print"}],"subject":[],"published":{"date-parts":[[2026]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"PSMA for HCC: a new frontier in precision medicine for liver cancer?","name":"articletitle","label":"Article Title"},{"value":"Cancer Treatment and Research Communications","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ctarc.2026.101169","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 istituto Romagnolo per lo studio dei tumori IRCCS IRST. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"101169"}}